ABOUT US
关于我们
Dr. Zhican Qu
Chairman and Chief Scientist of Nanolattix Group
Dr. Qu earned her bachelor's and master's degrees from Tsinghua University and her Ph.D. from Johns Hopkins University, subsequently completing her postdoctoral research at Washington University School of Medicine.
As a Principal Investigator (PI) at Southern Research Institute (SRI), Dr. Qu led an anticancer drug discovery program, dedicating her efforts to oncology research and development.
With over 30 years of accumulated expertise in cancer research and anticancer drug development, Dr. Qu currently spearheads Nanolattix Group's research initiatives in Antibody Drug Conjugates (ADC) and Radionuclide Drug Conjugates (RDC) development.
